a public good project by the
Synthesis
Company
of California

© 2026

Athanasios Tsianakas | doi.page

0 works0 citations0 h-index

Athanasios Tsianakas

Christoffel Blinden Mission(DE)Zentralklinik Bad Berka(DE)Klinik für Psychosomatik(DE)

Publications by Year

Research Areas

Dermatology and Skin Diseases, Psoriasis: Treatment and Pathogenesis, Cutaneous lymphoproliferative disorders research, Allergic Rhinitis and Sensitization, Asthma and respiratory diseases

Most-Cited Works

→ Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial(2018)630 cited
→ Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells(2008)153 cited
→ Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis(2018)132 cited
→ Chronic Prurigo of Nodular Type: A Review(2017)121 cited
→ Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study(2016)101 cited
→ Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial(2020)93 cited

→ Scalp necrosis in giant cell arteritis: Case report and review of the relevance of this cutaneous sign of large-vessel vasculitis(2009)

72 cited

→ Transition of pityriasis lichenoides et varioliformis acuta to febrile ulceronecrotic Mucha-Habermann disease is associated with elevated serum tumour necrosis factor-alpha(2005)68 cited

→ Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial(2017)64 cited

→ Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study(2019)62 cited